Treatment of Wilson's Disease in Asymptomatic Patients Without Significant Liver Involvement
This protocol addresses Wilson's disease in patients who are asymptomatic and show no signs of significant liver involvement, including those identified through family screening.
Clinical Scenario
The patient is asymptomatic with no signs of significant liver involvement. This includes individuals diagnosed incidentally through family screening. Treatment is indicated for this population, with timing considerations depending on age at diagnosis.
Treatment Approach
Either zinc-based therapy or chelating agents may be used; zinc salts are generally the initial choice for asymptomatic patients. Full agent selection, timing, and complete regimen details are in the protocol below.
Specific agent, dosing, schedule, and monitoring criteria are available in the full structured protocol.
Treatment Goals
- 24-hour urinary copper excretion within the established target range on maintenance treatment
- Serum zinc level at or above the defined therapeutic threshold
- Urinary zinc within the expected range for adequate therapy
References
DOI: 10.1016/j.jhep.2024.11.007
- Either zinc or chelators may be used in asymptomatic patients without signs of significant liver involvement (LoE 4, weak recommendation, consensus).
- Zinc salts are usually used for the first-line treatment of asymptomatic patients and for maintenance therapy after initial de-coppering with D-penicillamine or trientine.
- Asymptomatic patients diagnosed by family screening should receive treatment after 2-3 years of age.
- 24-h urinary copper excretion: 30-75 µg (0.5–1.2 µmol)/24 h on maintenance treatment.
View source ↗